-
Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program
HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the…
-
Kikkoman Hosts the 4th All-India Kikkoman Cooking Contest
Theme: ‘Surprising Ingredient Pairings’ – Students and Professionals Redefine the Potential of Kikkoman Naturally Brewed Soy Sauce NEW DELHI, July 1, 2026 /PRNewswire/ — On 26 February 2026, Kikkoman India hosted the 4th All-India Kikkoman Cooking Contest at IHM Pusa, Delhi. This year’s theme challenged participants to create an original dish featuring Kikkoman Soy Sauce through…
-
IFQM Symposium 2025 Concludes with a Call for Quality & Innovation to Make India Globally Competitive
New Delhi, Delhi, India India is at the cusp of developing and making products for the world, with quality that is of international standards, especially in the electronics and semiconductor industry, and MSMEs and startups have huge potential. It is not a distant ambition but a fast-emerging reality, but does India have the hunger to…
-
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash,…
-
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
